Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with cervical cancer at a specific stage (FIGO 2018 stages IB2 or IIA2, with a tumour between 2 and 4 cm, confirmed by MRI scan)
• People whose cervical cancer has been confirmed by tissue testing to be one of three types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• People aged between 18 and 75 years old
• People who are generally able to carry out daily activities with little to no limitation (confirm with trial site regarding the specific scoring scale used)
• People who have not received any prior treatment for their condition
• People whose life expectancy is at least 6 months
• Women who could become pregnant must agree to use contraception during the study and for 6 months after it ends, must have a negative pregnancy test within 7 days before joining, and must not be breastfeeding
• People whose blood test results show the heart, liver, kidneys, and bone marrow are functioning adequately, with those tests taken within 7 days before treatment starts
• People who willingly agree to participate, sign a consent form, are able to follow the study requirements, and are able to attend follow-up appointments

Who may not be able to join:

• People whose cancer type or stage does not match the specific types and stages listed in the inclusion criteria above
• People who have had a severe allergic reaction (Grade 3 or higher) to cisplatin, paclitaxel, Ivonescimab, or any ingredients in these medications
• People who have taken part in another clinical trial within the 4 weeks before enrolling
• People who have received an inactivated vaccine within 30 days before the first treatment, or who plan to receive one during the study
• People who have received certain immune-boosting treatments (such as interferons, interleukins, or combination vaccines) within 6 weeks or 5 half-lives before the first dose, whichever is shorter
• People who have been diagnosed with an immune system deficiency, or who have been taking steroid medication at higher than a specified dose, or any other immune-suppressing treatment within 7 days before the first dose
• People who have an active autoimmune disease that required ongoing medical treatment within the past 2 years
• People who have a history of non-infectious lung inflammation that required steroid treatment, or who currently have this condition
• People who have an active infection that requires ongoing medical treatment
• People with a known history of HIV infection
• People with a known history of hepatitis B (indicated by a reactive HBsAg test) or active hepatitis C infection (indicated by detectable HCV RNA)
• People with a known history of active tuberculosis
• People who have previously received a transplant of tissue or a solid organ from another person
• People who have cancer that has spread to the brain or central nervous system
• People with uncontrolled fluid build-up around the lungs or in the abdomen
• People whose ability to move is significantly limited due to bone fractures caused by cancer spread to the bones
• People whose bone marrow is not functioning well enough, based on specific blood test thresholds (confirm with trial site)
• People with significant liver abnormalities based on blood tests or liver disease markers, including certain levels of liver enzymes, bilirubin, or signs of advanced liver disease (confirm with trial site for specific values)
• People with significant kidney problems, including reduced kidney filtering ability, high levels of protein in the urine, kidney failure requiring dialysis, or a history of nephrotic syndrome (confirm with trial site for specific values)
• People with certain bleeding risks, including abnormal clotting test results, a history of bleeding disorders, use of certain blood-thinning medications, active gastrointestinal bleeding in the past 3 months, or a significant bleeding event within 4 weeks before the first dose
• People with certain heart or blood vessel problems within the past 6 to 12 months, including heart attack, serious heart rhythm problems, heart failure, stroke, blood clots in the veins or lungs, reduced heart pumping function, an abnormal heart electrical reading beyond a specified threshold, or uncontrolled high blood pressure (confirm with trial site for specific values)
• People who, in the opinion of the trial investigators, have other factors that could affect the study results or their safety, such as alcohol or drug dependency, serious mental illness, other serious medical conditions requiring treatment, or significant family or social circumstances

Important: Always verify eligibility with the trial site directly before applying.